In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) closed the day trading at $4.65 down -7.92% from the previous closing price of $5.05. In other words, the price has decreased by -$7.92 from its previous closing price. On the day, 5.1 million shares were traded.
Ratios:
For a better understanding of XERS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.17 and its Current Ratio is at 1.72.
On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $5.
On August 28, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $4.50.Craig Hallum initiated its Buy rating on August 28, 2023, with a $4.50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 09 ’25 when Fairley Ricki Louise bought 56,667 shares for $4.90 per share.
Hecht Beth sold 40,000 shares of XERS for $217,244 on Mar 20 ’25. The insider now owns 1,353,510 shares after completing the transaction at $5.43 per share. On Mar 20 ’25, another insider, Hecht Beth, who serves as the Officer of the company, bought 40,000 shares for $5.14 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.35.
Stock Price History:
Over the past 52 weeks, XERS has reached a high of $6.07, while it has fallen to a 52-week low of $2.03. The 50-Day Moving Average of the stock is -1.66%, while the 200-Day Moving Average is calculated to be 25.76%.
Shares Statistics:
A total of 156.01M shares are outstanding, with a floating share count of 147.66M. Insiders hold about 7.80% of the company’s shares, while institutions hold 54.44% stake in the company.
